OraVescent Fentanyl

Phase 3Small molecule

CCephalon

OraVescent Fentanyl is one of 32 small molecule programs targeting Chronic pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PainActive, not recruiting

Chronic PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

193 competitors in Chronic Pain

#DrugCompanyPhaseTrials

Tramadol Plus Acetaminophen

Johnson & Johnson

Phase 3

2 2

Opana

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 3

Naloxone Hydrochloride

PPurdue Pharma LP

Phase 3

2 4

MS Contin

Merck & Co.

Preclinical

3 5

OraVescent Fentanyl

CCephalon

Phase 3

1 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

2 7

Dayvigo

Eisai

Preclinical

1 8

Intuniv

PPromius Pharma, LLC

Preclinical

1 9

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breakthrough Pain3 trials

OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Completed·CCephalon·Phase 3·NCT00105937·300 enrolled

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Completed·CCephalon·Phase 3·NCT00228605·500 enrolled

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Completed·CCephalon·Phase 3·NCT00105287·100 enrolled

Efficacy and Safety2 trials

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

Completed·CCephalon·Phase 3·NCT00214942

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain

Completed·CCephalon·Phase 3·NCT00214955·120 enrolled

Chronic pain1 trial

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Completed·CCephalon·Phase 3·NCT00343733·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for OraVescent Fentanyl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OraVescent Fentanyl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OraVescent Fentanyl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cephalon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCephalon

OraVescent Fentanyl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breakthrough Pain3 trials

Efficacy and Safety2 trials

Chronic pain1 trial

References

Drug Info

Quick Facts

Related News